Phase 3 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the oesophageal or stomach cancer group (OGA):
- People who have given voluntary written consent before any screening takes place (or whose legal representative has done so)
- People aged 18 or older
- People with a newly confirmed diagnosis of adenocarcinoma of the oesophagus or stomach, proven by tissue or cell sample
- People who have already had a specific type of imaging scan called an [18F]FDG PET/CT
- People whose cancer has been staged as not yet spread to distant parts of the body (confirm with trial site)
For the pancreatic cancer group (PDAC):
- People who have given voluntary written consent before any screening takes place (or whose legal representative has done so)
- People aged 18 or older
- People with a newly confirmed diagnosis of pancreatic ductal adenocarcinoma, proven by tissue or cell sample
- People who have had an [18F]FDG PET/CT scan, or standard staging with a CT or MRI scan
- People whose cancer has been staged within a certain range, excluding those whose cancer is immediately removable by surgery (confirm with trial site)
For the "clinically challenging" group:
- People who have given voluntary written consent before any screening takes place (or whose legal representative has done so)
- People aged 18 or older
- People with a confirmed diagnosis of any cancer, proven by tissue or cell sample
- People who have had an [18F]FDG PET/CT scan
- People who have unexplained symptoms, complaints, abnormal blood test results, or unexplained findings on imaging scans
Who may not be able to join:
- People who are unable to understand the study design or are unwilling or unable to complete all study procedures
- People with any condition or disorder that the investigator believes could affect their safety or ability to follow the study procedures
- People who have received or are receiving any treatment that could affect their safety or the reliability of the trial results
- Women who are pregnant, breastfeeding, planning to become pregnant, or who are capable of becoming pregnant and are not using a highly effective form of contraception as specified by the trial (confirm with trial site for details on accepted contraception methods)
- People currently participating in another clinical trial involving an investigational medicine or device, where the two trial designs are not considered compatible by the study team
- People who have taken part in a scientific study in the last 12 months where the experimental procedures resulted in radiation exposure greater than 1 mSv
- People with a known allergy or hypersensitivity to the imaging agent [18F]AlF-FAPI-74 or its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Primary Objective OGA: demonstrate superiority of [18F]AlF-FAPI-74 PET/CT over [18F]FDG PET/CT.; Primary Objective PDAC: demonstrate superiority of [18F]AlF-FAPI-74 PET/CT over conventional imaging (CT or MRI) or [18F]FDG PET/CT (if available); Primary Objective Clinically Challenging Situation: demonstrate contribution of [18F]AlF-FAPI-74 PET/CT in this setting.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.